{"nctId":"NCT02021656","briefTitle":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection","startDateStruct":{"date":"2013-12-10","type":"ACTUAL"},"conditions":["Chronic HCV Infection"],"count":384,"armGroups":[{"label":"LDV/SOF","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* HCV treatment-naive, as defined as no prior exposure to any interferon (IFN) or other approved or experimental HCV-specific direct-acting antiviral agent; OR HCV treatment-experienced with medical records that include sufficient detail of prior IFN-based treatment to allow for categorization of prior response as either intolerant, non-responder, or experienced viral breakthrough or relapse.\n* Genotype 1 HCV at screening\n* HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy\n\nKey Exclusion Criteria:\n\n* Pregnant or nursing female\n* Chronic liver disease of a non-HCV etiology\n* Current or prior history of any clinically-significant illness (other than HCV)\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, \\< 25 IU/mL in Korea and Taiwan and \\< 15 IU/mL in China) 12 weeks following the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Breakthrough","description":"Viral breakthrough were defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) during treatment, but did not achieve a sustained virologic response (SVR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Relapse","description":"Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"HCV RNA and Change From Baseline in HCV RNA Through Week 12 for China Only","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.31","spread":"0.633"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":"0.633"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":384},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Headache"]}}}